RT @annalsthorsurg: 🏆Congratulations to Dr. J. W. Awori Hayanga, named the 2024 General Thoracic Reviewer of the Year from West Virginia Un…

RT @ElliotServaisMD: Going to STS annual meeting? @STS_CTsurgery Like robotic surgery? @IntuitiveSurg Like to eat food? If yes, then i…

RT @Innovationsjour: 1⃣st article in our Vol 19, Issue 5 Focused Topic Series is from Drs D’Souza, Kneuertz, and Cheufou on the 7 Pillars o…

RT @annalsthorsurg: #GeneralThoracic #CME article from Brown et al on Predictors of Discharge With Supplemental Oxygen After Lobectomy for…

RT @drbypass: Happy New Year all ISMICS friends around the world! Wishing you All the Best in 2025!! That includes getting your abstract ac…

@ElliotServaisMD @ZaidAbdelsattar @GavittWoodard @hari_keshava @AltorkiNasser @JonesDavid2013 @okusanyamd @NateEvansMD I should clarify that may have been resectable with very large & extensive operation, but did not feel that was appropriate without neo first. Regardless, too complicated to discuss on X. Happy to grab coffee at STS & get others thoughts as many options on how to handle this one

@hari_keshava @ElliotServaisMD @ZaidAbdelsattar @GavittWoodard @AltorkiNasser @JonesDavid2013 @okusanyamd @NateEvansMD Exactly what Hari said. For non-pancoast I agree- often get great results with chemoIO even if low PDL1. Difference is guidelines support it. Hard to go off guideline for pancoast (chemoRT) unless there’s a compelling reason. But every patient is unique…

@ZaidAbdelsattar @ElliotServaisMD @GavittWoodard @hari_keshava @AltorkiNasser @JonesDavid2013 @okusanyamd @NateEvansMD Agree still standard, however had case of intraoop surprise of unresectable pancoast- aborted. High pdl1, so after tumorboard, gave chemoIO. Became a fairly straight forward RUL, albeit sticky. Complete path response. Can’t change practice guidelines on single anecdotes tho.

@SethBKrantz @biniamkidaneMD @ShandaBlackmon @WomenInThoracic @STS_CTsurgery @OfficialSTSA @IASLC @jdphillipsMD @AltorkiNasser @DoctorJSpicer @ElliotServaisMD @jdoningtonmd @ekslim @BrendonStilesMD Agree, don’t think more local treatment makes sense at this point. We discuss this a lot at our tumor board (high risk stage 1b)- not giving adjuvant at this point, regardless of extent of resection.

RT @helops79: Looking for opinions, following my dear colleagues examples: Young woman, carrier of a MEN1 germline mutation, with multiple…

RT @AndrewBrownlee: Mixed emotions. Back in Chicago for the clinical retirement of our mentor and legend Mark Ferguson. Couldn’t ask for a…

RT @huntsmancancer: We are honored to share that @TomVargheseJr has been named the new editor-in-chief of the Journal of the American Colle…

@BrendonStilesMD @ElliotServaisMD @Suture_UK @ChrisGeeOrtho @BBASS_skills @Rungichungi @LiangRhea @otolaryngolofox @mstotty88 @MarkBagnallSurg @rbarbosa91 @David_ukan @TomVargheseJr @ShandaBlackmon @okusanyamd @AltorkiNasser @WCM_CTSurgery A little bit more from Pearson’s AATS address & impact Belsey made on surgeons in Toronto, Chicago, and other places:

RT @surgeonapp1: Happening tomorrow at 8 PM ET! Join us on SurgeOn Live for the Thoracic Surgical Mastery Series, featuring @ErinGillaspie…

RT @surgeonapp1: Only a few days left until the Thoracic Surgical Mastery Series focusing on "Lobe, Segment, Wedge: Deciphering the Data &…

@UofUSurgery It’s clearly a unicorn 🦄

RT @surgeonapp1: Don’t miss @ErinGillaspie, @NateEvansMD & @BrianMitzman on Thoracic Surgical Mastery Series next week! Moderated by @Ellio…

RT @STS_CTsurgery: Early career surgeons, don't miss the Early Career Journey webinar on Student Loan Management! Get insights on repayment…

@ElliotServaisMD @TomVargheseJr @acsJACS